1	A novel method to assess motor planning deficits in patients with
2	Parkinson's disease and mild cognitive impairment
3	¹ Natalie J Maffitt, ² Sattwika Banerjee, ² Subhajit Sarkar, ² Suchismita Majumdar, ² Supriyo
4	Choudhury, ² Hrishikesh Kumar, ¹ Demetris S Soteropoulos, ¹ Alexander Kraskov*
5	¹ Biosciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom
6	² Institute of Neurosciences Kolkata, Kolkata, India
7	* Corresponding author: sasha.kraskov@newcastle.ac.uk
8	Running title: Motor planning deficits in Parkinson's disease
9	Number of:
10	Pages - 22
11	Figures - 8
12	Tables - 0
13	Multimedia - 0
14	3D models - 0
15	Words in:
16	Abstract - 150
17	Introduction - 798
18	Discussion - 1790
19	Conflict of interest
20	All authors declare no financial or non-financial competing interests.
21	Acknowledgements
22	This work was supported by grants BB/P006027/1 (AK), BB/Y000625/1 (AK), Newcastle Neuroscience
23	Fund (NJM). The funders had no role in study design, data collection or interpretation, nor in the
24	decision to submit the work for publication. The authors thank Mr Norman Charlton for mechanical
25	engineering of the experimental setup, and Prof. Stuart Baker for designing the contact circuit and
26	initial Sequencer scripts.
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Author Contribution

- 28 NJM, HK, SC, DSS and AK designed the study. NJM, DSS and AK programmed the behavioural paradigm.
- 29 NJM collected and processed data, performed analyses, prepared all figures and wrote the manuscript.
- 30 SB, SS and SM collected data. AK performed analyses. SC, HK, DSS and AK provided resources. DSS and
- 31 AK edited the manuscript and supervised. All authors read and approved the final manuscript.
- 32

27

Data Availability

- 33 All data generated or analysed during this study are available from the corresponding author upon
- 34 reasonable request.

36

Abstract

37 It is well established that patients with Parkinson's disease (PD) show deficits with movement 38 execution, however experiences of motor planning dysfunction, and how they relate to the severity of 39 motor symptoms, remains unclear. To investigate motor planning in PD, we designed a novel precision-40 grip task. PD patients showed significantly higher uncertainty in task performance compared to healthy 41 controls, indicative of motor planning deficits. Performance of PD patients did not correlate with 42 indicators of disease severity or subtype, yet patients on a higher daily levodopa dosage showed 43 reduced motor planning deficits. Interestingly, these deficits were present even in recently diagnosed patients, implying that this measure may have potential as an early marker of motor planning 44 impairment. These results suggest that the motor planning deficits revealed by our task may arise from 45 46 separate pathological processes to that of motor execution dysfunction in PD, though can be alleviated 47 with higher treatment dosages. **Keywords** 48

49 Parkinson's disease; Motor planning; Grasping; Ambiguity; Mild cognitive impairment; Dopamine.

51

Introduction

52 Whilst the defining characteristics of patients with motor disorders are difficulties in generating and 53 controlling movement, additional features of cognitive dysfunction are also commonly experienced. 54 For patients with Parkinson's disease (PD), this can range from minimal cognitive impairment in, for 55 example, mood regulation or executive function, to extreme clinical pictures of severe dementia ¹. Of 56 these deficits, impairments in motor planning can have consequences for successful interaction with 57 our environment in how they perform day to day physical tasks, yet such impairments have 58 comparatively received much less focus.

59 Our understanding of motor planning deficits in PD initially developed within the context of action 60 imitation tasks. Sharpe, Cermak and Sax (1983), showed that when asked to perform either familiar 61 gestures from memory or unfamiliar gestures post observation, PD patients only make greater spatial 62 errors compared to controls when performing unfamiliar gestures ². It has been suggested that such errors are a consequence of defective encoding and processing of visuospatial information, since the 63 64 neural mechanisms needed to perform successful action imitation rely more heavily on the accuracy of visuospatial encoding than when an individual is responding to verbal command ^{3,4}. Yet, these spatial 65 errors could also be influenced by memory recall deficits; PD patients show greater impairment when 66 67 imitating movement sequences compared to single actions³. Thus, the motor planning performance 68 of individuals with PD when intending to enact their own self-chosen movement, rather than one 69 rehearsed from memory or by way of imitation (i.e. less reliant on successful visuospatial encoding or 70 recall), remains to be explored.

71 Additional evidence for the presence of motor planning abnormalities in PD has been implied from 72 reaction time (RT) tasks. For simple RT tasks, whereby the subject knows in advance the target location 73 or required action but is instructed to wait for a go signal before initiating movement, consistent slowing of RT is observed in comparison to healthy controls (e.g. ^{5,6}. There have been suggestions that 74 75 this delay may not solely be a manifestation of bradykinesia, but rather could reflect problems in releasing motor commands or in the pre-programming of them ^{7,8}. Contrastingly, in choice RT tasks, 76 77 several actions are presented and the one required is only revealed at the time of the go cue. Not only, 78 however, do reported deficits in choice RT tasks remain controversial due to the seemingly task-79 dependency nature of the findings, but visual processing time, which has been shown to be hindered 80 in PD, is consistently an uncontrolled factor in both forms of RT tasks ⁹⁻¹².

In this study, we used the context of motor ambiguity in a reach-to-grasp task as a method to
 investigate motor planning capabilities in patients with PD, in a task adapted from Stelmach *et al.*, 1994
 ¹³. In this context, motor ambiguity can be described as situations whereby the motor action (i.e. wrist

84 posture) performed upon a target object is variable, despite the visual-spatial properties of the object 85 remaining the same. For a healthy person, the decided motor action for a task, such as picking up an 86 object with the wrist pronated, is decided by individualised comfort preferences, leading to an 87 optimised and consistent action choice based on previous learned experience. However, some motor ambiguity will nevertheless persist when the optimal preference cannot be identified and therefore 88 89 planned. We hypothesised that when performing a reach-to-grasp task, patients with PD would show 90 greater ambiguity in wrist posture selection as a consequence of impaired motor planning in 91 comparison to healthy controls.

92 Given that the characteristics of PD consist of both motor and non-motor deficits, it was of interest to 93 also investigate motor planning performance in individuals who experience cognitive dysfunction 94 without motor execution deficits. We therefore recruited patients diagnosed with mild cognitive 95 impairment (MCI), a cohort that experience cognitive deficits in memory, language and other cognitive 96 domains, though without significant daily disruption to be classified as dementia and notably absent 97 of any basic motor deficits ¹⁴. It has been shown previously that MCI patients may also experience visual-motor difficulties when their cognitive load is high: they are slower to plan movements and have 98 99 difficulties integrating visual perception with motor action, though in simpler cognitive tasks such as 100 standard reach-to-grasp, performance and planning deficits are less pronounced ¹⁵⁻¹⁷. In this study, we 101 explored the possibility that in pre-dementia, the extent of motor ambiguity may reflect the weight of 102 cognitive load induced by our grasping task and thus reveal any impairments in motor planning; we 103 hypothesised any such deficits will occur to a minimal extent given the predictive cognitive simplicity 104 of the task.

105 We reveal not only that motor planning is affected in both PD and MCI in comparison to healthy 106 controls, but also that for PD patients it can be influenced by daily treatment dosage with levodopa, 107 suggestive of a therapeutic influence of dopamine on motor planning.

108

109

Methods

110 Participants

This study was conducted in a total of 60 participants within the Neurology Outpatient Department of 111 a tertiary care referral centre in Eastern India. Ethical approval was obtained from the Institutional 112 113 Research Ethics Committee of the Institute of Neurosciences, Kolkata; written informed consent was 114 taken from all volunteers. This study was performed in accordance with the guidelines established in the Declaration of Helsinki, except that the study was not preregistered in a database. Healthy 115 116 volunteers were selected from the care givers of the patients attending the Neurology Outpatient 117 Department; all had normal cognition (MOCA \geq 26), and no apparent neurological disease. PD patients 118 were diagnosed using UK Brain Bank diagnostic criteria for PD; exclusion criteria for participation in 119 this study included presence of dyskinesia, severe cognitive impairment (MOCA < 10), and profound physical impairment (Hoehn & Yahr stage > 4) or an inability to perform prehension movements. 120 121 Inclusion criteria for the MCI cohort consisted of a MOCA score indicating mild cognitive impairment at the time of assessment (MOCA < 26 and > 10) and a complete absence of any signs of motor 122 123 execution dysfunction. All participants were right-handed and naïve to the experiment and its 124 predictions.

125 Due to low trial counts (< 50% complete), 7 participants (6 PD, 1 Control) were excluded from analysis. Remaining in the study were 15 healthy controls (8 females; 51.8 ± 9.6 years STD), 27 patients 126 diagnosed with idiopathic PD (IPD; 12 females; 60.9 ± 10.7 years), and 11 MCI patients (5 females, 63.5 127 ± 7.5 years). All PD patients were receiving regular levodopa treatment (mean daily levodopa 128 129 equivalent dosage (LED) 511.0 ± 278.6 mg) and assessed in their ON state. Conversion formulae for LED calculation were in accordance with widely accepted proposals ¹⁸. 130

131 Clinical scoring

132 The disease severity of each patient was assessed using standard disease severity scales: for MCI, the 133 Montreal Cognitive Assessment (MOCA); for PD, the Movement Disorders Society Unified Parkinson's 134 Disease Rating Scale-III (MDS UPDRS III) and MOCA. The MOCA and/or UPDRS assessment were 135 performed immediately preceding or following the main task by a trained professional.

136 Task set-up

137 The experimental paradigm required participants to perform a precision grip movement on a triangular prism block (6 cm long by 2 cm wide, see Figure 1 and previous paper ¹⁹) with their right-hand upon 138 hearing a go cue (auditory beep 500 Hz, lasting 50 ms). The target object was designed with the 139 intention to afford only one possible grasp: the thumb and finger at opposing ends of the prism block 140 141 ¹³. The object was mounted onto a grey rectangular stage and connected to a stepper motor to enable

142 rotation in steps of 0.9° angles - the stepper motor was driven by an Arduino UNO R3 and motor shield 143 R3, and controlled by custom written Arduino scripts. Thin triangular metal plates were glued to each 144 end of the prism block and connected to a custom made circuit that allowed detection of skin contact 145 by a change in impedance. By placing a glove onto the index finger to impede contact with the object, hand orientation selection could be recorded in terms of thumb placement, either 'Grasp 1' whereby 146 147 the thumb was placed on the left or top end of the object or 'Grasp 2' whereby the index finger was used instead (Figure 1). Previously studies have referred to these two grasp postures as 'thumb-148 149 left'/'supination' or 'thumb-right'/'pronation' respectively (e.g. Stelmach et al., 1994; Wood and 150 Goodale, 2011), however given both of these nomenclatures lose validity at certain positions we opted 151 for Grasp 1/ Grasp 2.



152

Figure 1. Experimental set-up. Participant is seated with LCD goggles covering their visual field and head placed on a chin rest. Their right wrist is used to press the home-pad button to initiate trial sequence. A latex glove on the index finger impedes touch with the contact circuit on the target object, allowing detection of wrist posture (Grasp 1 or Grasp 2) on a trial-by-trial basis.

Participants were seated in a chair with their wrist positioned on a circular 'home-pad' button (6 cm in diameter) as the starting location. The target object was positioned 31 cm anterior to the centre of the home pad and 14.5 cm superior, with its rotation occurring in the frontal plane. This resulted in the object lying 27 cm to the right of the body's midline.

As comfort and therefore choice of grasp has been shown to be sensitive to body and head posture ²⁰, a chin rest was used to mitigate any postural shifting that could introduce unwanted variability to behaviour. Participants wore LCD goggles (PLATO goggles; Translucent Technologies, Toronto, Canada) to occlude their vision between trials until the object had rotated into place at the target angle. The

transition time from opaque to visible was 4 ms. In cases where participants wore visual correctionglasses, the goggles were placed over the top and secured with a headband.

167 Task procedure

168 Beginning each trial with their wrist in mid-pronation to press down on the home-pad, participants were asked to lightly pinch their index finger and thumb together until the go cue. This wait time was 169 170 uniformly varied randomly from trial to trial (1000-1300 ms) to prevent participants acting on 171 anticipation of the go cue. Synchronous with an auditory beep, the goggles became transparent and 172 participants were asked to reach out as quick as possible and comfortably grasp the target object between their thumb and index finger, pinching it lightly. After object contact, they returned to the 173 174 home-pad to initiate the next trial sequence. If the home-pad was released too early (i.e. prior to the 175 go cue), an error tone would sound (200 ms, 200 Hz) to indicate the subject should return to the start 176 button. A total of 162 trials across 27 unique angles spaced by 4.5° (spanning 127.8°) were carried out 177 in a randomised sequence with equal incidence per angle.

178 Data and statistical analysis

179 Grasp choice data were gathered using the custom designed contact circuit and sampled at 5 kHz (CED 180 Micro 1401, Cambridge Electronic Design) using Spike2 software. All data analyses and statistics were 181 performed using custom written MATLAB scripts. Analysis resulted in three measures – the halfwidth (as described below), reaction time (RT), measured as time from go cue to home pad release, and 182 183 movement time (MT), measured as time from release of home pad to contact with the target object. 184 Trials for which RT was shorter than 150 ms were excluded from analysis; MTs had no explicit cut-off. 185 For both RT and MT analysis, remaining values were log transformed, with any trials outside the mean 186 \pm 3 SD excluded - this exclusion process was then repeated recursively until no more trials could be 187 excluded. On average across all participants, 3.3 % of the trials were discarded due to extremes of RT and 0.91 % for extremes in MT. 188

189 Choice of grasp was coded with reference to which edge of the target object the thumb made contact 190 with. The probability of using a 'Grasp 2' wrist posture was calculated for each target angle and a 191 logistic regression curve was fitted to the data using the function below, where x_0 is the subject's switch 192 point between the two choices, and k is a scaling parameter.

193
$$f(x) = \frac{1}{1 + e^{-k(x - x_o)}}$$

This sigmoid fitting allowed the 'halfwidth' to be calculated - a measure of switch sharpness, calculated as the difference between target angles for the 75% and 25% choice probabilities (= 2ln(3)/k). This was used as an indicator of subject uncertainty across the task as a whole.

Across each group population, numerical values were described using mean (± SD) and compared using one-way ANOVA with post hoc Tukey's test. The strength of correlation was estimated with Pearson's correlation coefficient R². For all three variables (HW, RT, MT), receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) calculated. An AUC of 0.5 indicates an identical distribution of the measure in patients and controls; an AUC of 1.0 occurs if the distributions are completely non-overlapping. Thus, a higher AUC value indicates greater utility of the measure as a diagnostic tool. Comparison of AUC values was performed using DeLong's test.

204

Results



205

Figure 2. Example psychophysics curves from an individual from each cohort. Shaded areas indicate the range of angles for which the probability of using a Grasp 2 posture over Grasp 1 is between 25 and 75%, yielding the measure 'Halfwidth'. IPD, idiopathic Parkinson's disease; MCI, mild cognitive impairment.

210 Figure 2 shows the average decisions in grasp choice for each target angle from single representative 211 subjects of each cohort, which illustrate the first main finding of our study. As previously reported, 212 when the target object is rotated across a range of angles, a typical healthy subject transitioned from 213 consistently using one grasp posture to using the other across a relatively narrow range, following a 214 sigmoid pattern (Figure 2a). The steepness to the sigmoid slope in this healthy subject is a consequence 215 of minimal variability in grasp choice across most angles, yielding a halfwidth value (indicated by 216 arrows) of 12.1°. By contrast, for the individual with IPD, there are greater target angles for which grasp choice is not consistent, leading to a wide ambiguity zone with a halfwidth value of 34.6° (Figure 2b). 217 218 Similarly for the single subject with MCI (Figure 2c), variability in grasp choice occurs over a wider 219 range of angles, yielding a larger halfwidth value (19.3°) than the example healthy control.



Figure 3. Halfwidth values and receiver operating characteristic (ROC) curves for control, PD, and 222 MCI subjects. a) Halfwidth values for every participant in each cohort. The example data shown in 223 224 Figure 2 is highlighted here by thicker outline on the individuals' data point. b) ROC curves confirming that halfwidth can effectively separate healthy controls from both PD and MCI patients. Dotted 225 226 diagonal line indicates the expected result if halfwidth did not discriminate between groups. IPD, 227 idiopathic Parkinson's disease; MCI, mild cognitive impairment. Error bars represent mean ± 1 STD. * P < 0.05; *** P < 0.0001; ns, not significant. 228

229 For all subjects within each group, the halfwidth of the sigmoid curve was calculated, shown by each 230 individual dot in Figure 3a. The healthy control cohort had a lower mean halfwidth value than each 231 patient group (Figure 3a; Control mean = 12.86 ± 5.09 °; IPD mean = 25.90 ± 8.84 °; MCl mean = 21.76232 \pm 7.04 °; ANOVA p < 0.0001). Post-hoc t-tests between the healthy control group and both IPD and MCI 233 patient groups indicated significant differences in halfwidth (IPD p < 0.0001; MCI p = 0.049), however 234 there was no significance difference between the IPD and MCI cohorts (p = 0.098).

235 Given halfwidth was significantly different between each patient group and healthy controls, it was of interest to investigate whether this difference was significantly robust to distinguish motor planning 236 237 pathology from health. This is explored in Figure 3b, which presents receiver operating characteristic 238 (ROC) curves for both IPD and MCI cohorts. The area under the ROC curve for HW was 0.916 and 0.867 239 for IPD and MCI cohorts respectively; both values were significantly higher than 0.5, the value 240 associated with entirely overlapping distributions, (p < 0.005 for both, Monte Carlo test, 10,000 241 iterations).



243



Figure 4. Severity scales and clinical subtype for PD patients. Data is unavailable for four PD patients 244 for Hoehn and Yahr stage, and eight for time since diagnosis. Clinical subtype is categorised based on 245 246 UPDRS scoring. IPD; idiopathic Parkinson's disease; TD: tremor dominant; PIGD: postural and gait 247 instability dominant; ns: no significance. Error bars represent mean ± 1 STD.

To explore whether the observed difference in PD patients from controls was related to disease 248 249 severity or clinical subtype, UPDRS assessment was carried out. Interestingly, there was no significant correlation between UPDRS part III score and sigmoid halfwidth (Figure 4a; $R^2 = 0.014$, p = 0.551). 250 251 Similarly, there was no correlation between halfwidth and time since diagnosis (Figure 4c; $R^2 = 0.01$, p 252 = 0.634). Furthermore, there was no significant difference in halfwidth between those of Hoehn and 253 Yahr stage 1, and those of stage 2 (Figure 4b; Stage 1 mean = 25.04 ± 6.09 ; Stage 2 mean = $29.38 \pm$ 254 11.93; unpaired t-test p = 0.248). Nor did the clinical subtype of PD (tremor dominant – TD, versus

- 255 postural and gait instability dominant - PIGD) have any significant bearing on halfwidth (Figure 4d;
- PIGD mean = 22.37 ± 6.40 ; TD mean = 27.98 ± 9.57 ; unpaired t-test p = 0.112). 256



257

264

258 Figure 5. Effect of levodopa on halfwidth for PD patients. Total daily levodopa equivalent dosage (LED) 259 was calculated for each subject receiving treatment.

Despite finding no correlation between severity of motor symptoms and halfwidth, surprisingly for PD 260 261 patients there was a significant effect of daily levodopa equivalent dosage (LED) on sigmoid halfwidth 262 (Figure 5; $R^2 = 0.29$, p = 0.004). Interestingly, the higher the daily treatment dosage, the lower the 263 halfwidth value and closer to the mean healthy control value (dashed grey line) subjects became.



Figure 6. Effect of levodopa on reaction and movement times for PD patients. Total daily levodopa 265 equivalent dosage (LED) was calculated for each subject receiving treatment. RT, reaction time; MT, 266 267 movement time.

268 Though LED correlated with our halfwidth measure, it did not correlate with RT (Figure 6a; $R^2 = 0.05$,

269 p = 0.250) or MT (Figure 6b; IPD R^2 = 0.06, p = 0.225).





273 The effect of global cognitive score and age on halfwidth are shown in Figure 7a-c and 7d-f respectively. The age of the subject had no significant influence on their grasp choices for any cohort (Figure 7a-c; 274 IPD $R^2 < 0.01$, p = 0.838; MCI R^2 = 0.01, p = 0.728; Controls R^2 = 0.01, p = 0.669). Notably, for MCI 275 276 patients, there was a significant correlation between MOCA score and halfwidth (Figure 7d; $R^2 = 0.76$, 277 p < 0.001), with a higher MOCA score (i.e. stronger cognitive abilities) increasing the likelihood of a 278 smaller halfwidth value. However, for both the PD cohorts and healthy controls this relationship was 279 not found (Figures 7f, 7a; IPD $R^2 < 0.01$, p = 0.883; Control R^2 = 0.05, p = 0.446).



280

Figure 8. Reaction time (RT) and movement time (MT) values and receiver operating characteristic 281 282 (ROC) curves for control, PD, and MCI subjects. a-b) RTs and MTs of all control, PD, and MCI subjects. c-d) ROC curves confirming that RT and MT can effectively separate healthy controls from both PD and 283 MCI patients. Dotted diagonal line indicates the expected result if halfwidth did not discriminate 284 285 between groups. IPD, idiopathic Parkinson's disease; MCI, mild cognitive impairment. Error bars 286 represent mean ± 1 STD. * P < 0.05; ** P < 0.005; ns, not significant.

287 As expected, healthy controls were quicker to release the home-pad upon receiving the go-cue 288 compared to all other patient groups (Figure 8a; healthy mean $RT = 0.39 \pm 0.05$ s; MCI mean RT = 0.51289 \pm 0.11 s; IPD mean RT = 0.52 \pm 0.14 s). An ANOVA indicated a significant effect of group (healthy, MCI, 290 IPD; p = 0.002) on RT, with post-hoc t-tests indicating significant difference between healthy controls 291 and both IPD (p = 0.001) and MCI (p = 0.029) patient groups. No significant difference in RT between 292 IPD and MCI was found (p = 0.883).

- 293 Healthy subjects were also quicker to move from the home-pad to make contact with the target object
- 294 compared to the patient groups (Figure 8b; healthy mean MT = 0.83 ± 0.14 s; IPD mean MT = $1.27 \pm$
- 295 0.52 s; MCI mean MT = 1.17 ± 0.16 s). An ANOVA indicated a significant effect of group (healthy, MCI,
- 296 IPD; p = 0.004) on MT, with post-hoc t-tests indicating significant difference between healthy controls
- 297 and the IPD patient group (IPD p = 0.003), but not MCI (p = 0.082). In addition, no significant difference
- 298 in MT was found between IPD and MCI (p = 0.759).

299 To assess the capabilities of RT and MT as diagnostic indicators, ROC curves were compiled, shown in 300 Figure 8c-d. The area under the ROC curve for RT was 0.840 and 0.806, and for MT was 0.788 and 301 0.945 for IPD and MCI patients respectively. All values were significantly higher than 0.5, the value 302 associated with entirely overlapping distributions, (p < 0.005 for all, Monte Carlo test, 10,000 iterations). For comparison, there was no significant difference in AUC value between HW and RT 303 304 either cohort (IPD Z = 1.30, p = 0.193; MCI Z = 0.38, p = 0.702; DeLong's test), nor between HW and 305 MT (IPD Z = 1.57, p = 0.116; MCI Z = -0.81, p = 0.419; DeLong's test).

306 Furthermore, there was no significant correlation between RT and halfwidth for any cohort (Control 307 $R^2 = 0.10$, p = 0.261; IPD $R^2 = 0.05$, p = 0.278; MCI $R^2 = 0.09$, p = 0.365), nor between MT and halfwidth (Control $R^2 = 0.02$, p = 0.646; IPD $R^2 = 0.01$, p = 0.639; MCI $R^2 = 0.02$, p = 0.71). 308

309

310

Discussion

311 In this study we introduced a novel approach for assessing motor planning capabilities in patients with 312 Parkinson's disease and mild cognitive impairment. Here, the presentation of a target object at varying 313 degrees of ambiguity in a simple reach-to-grasp task allowed us to probe motor planning uncertainty 314 by measuring grasp selection, an output of distinct motor plans. In agreement with previous studies, 315 we observed significant deficits in patients' task performance relative to healthy controls suggestive of 316 impairments in motor planning, in our case measured by the degree of uncertainty in wrist posture selection. However, unlike previous studies, the context of motor ambiguity in our task allowed the 317 318 assessment of motor planning capabilities without reliance on action imitation, memory recall, or

rapid visual inspection, skills that have been required in previous motor planning assessments ^{2,3,11,12}.

This, combined with evidence that greater uncertainty is present even in patients with a more recent diagnosis and with relatively minor cognitive impairment, suggests that grasp uncertainty is a sensitive

322 measure of motor planning impairment that could have utility as an early disease marker.

323 We found that the degree of uncertainty did not correlate with Hoehn and Yahr stage or UPDRS (Part 324 III) score, both established scales of PD disease progression scored by the extent of the severity of 325 motor symptoms. It is therefore likely that grasp uncertainty, rather than being a direct consequence 326 of motor execution impairment, actually captures a more cognitive deficit, specifically motor planning. 327 This is further evidenced by the lack of any significant difference in planning uncertainty between tremor dominant, and postural and gait dominant clinical phenotypic subtypes. Cognitive dysfunction 328 329 is frequently documented in PD patients at all stages of the disease, yet correlations with objective motor symptom scoring can be highly variable. For example, UPDRS (Part III) is often found to be a 330 331 weak or non-existent correlate to both global and specific measures of cognitive impairment ²¹⁻²⁵. In 332 addition, the lack of correlates between cognitive scoring and objective measures of motor control functioning ^{23,26-28}, and the presence of prodromal non-motor deficits prior to diagnostic motor 333 symptoms ^{29,30}, all exemplify the occurrence of cognitive deficits and their independence from other 334 pathological changes in PD. 335

336 The consequences of disease pathology likely consist of a multitude of cortical and subcortical network 337 changes that lead to further impairment beyond basic motor dysfunction, varying both between 338 individuals and over time. Non-motor symptoms can arise not only independent from the severity of 339 basic motor dysfunction as described above, but also independent from each other ³¹⁻³³. While deficits 340 in memory, attention, executive and visuospatial function are common, there exists a large heterogeneity to the profile of cognitive dysfunction in PD patients ³⁴. Our finding of the lack of 341 342 correlation between motor planning deficits and MOCA scores, a measure of global cognitive function 343 ³⁵, is therefore not unique, but instead builds towards an argument for distinct dysfunctional neural circuitry or neurochemical systems ²³. Depending on what elements of network circuitry become 344 345 impaired and the nature of interactions between them, different combinations of behavioural deficits could emerge to different extents, hence yielding the absence of correlation between our measure 346 347 and MOCA or UPDRS.

Despite the lack of correlation with disease severity scoring, patients who were receiving a higher total
 daily treatment dosage showed reduced motor planning deficits compared to those on lower dosages.
 Given that dosage is determined by the clinician primarily on the basis of the severity of motor
 symptoms ³⁶, one could initially interpret LED as a disease severity indicator. However, this would be

presumptuous given that dosage can fluctuate based on other clinical considerations such as the severity of negative side effects ³⁷. Alternatively, another interpretation of this relationship between LED and uncertainty could be that lower dosages of levodopa are insufficient to reduce motor planning deficits, meanwhile higher dosages are able to restore impaired processing. This amelioration may occur to a separate extent than that of improvements to motor function, as implied by the lack of correlation between dosage and MT.

358 Evidence for a cortical influence of levodopa administration has been accumulated based on drug induced behavioural changes in PD since soon after its introduction as a therapeutic drug ³⁸. 359 360 Hypomania, impulse control disorder, personality changes, and hallucinations are but a few examples of the common negative side effects of levodopa, however the pathophysiology remains unclear ³⁹. 361 362 Though cortical deficits in PD are typically treated with cholinesterase inhibitors acting on acetylcholine ²⁹, further evidence for levodopa having a cortical effect has manifested in studies 363 364 showing improved cognitive performance across a range of clinical assessment scales ⁴⁰⁻⁴², although 365 benefits are not always universal ⁴³. Nevertheless, these studies have primarily focussed on ON/OFF 366 states rather than comparative dosing effects. As the latter remains unknown, it could be speculated 367 that, based on our findings, some dysfunctional neural networks may require higher dosages of levodopa to correct compared to basic motor circuitry. This could be attributed to differences in 368 369 dopamine receptor density between cortical and subcortical regions; there are far fewer D_1 and D_2 370 receptors present in the frontal cortex compared to the basal ganglia ^{44,45}. Still, further exploration, 371 both with patients receiving higher dosages, and on-off experimental design are required to investigate 372 this speculative hypothesis.

373 For patients presenting with only mild cognitive impairment without any basic motor deficits, 374 uncertainty in motor planning was also observed, although to a slightly lesser degree than the PD 375 cohort. This adds to the suggestion that the planning deficits measured in PD are unlikely to be a 376 consequence of basic motor pathology, which is absent in these MCI patients. The MCI cohort also 377 showed significant prolongation of RT but only minor, insignificant delays of MT compared to healthy 378 controls. This is in agreement with indications from previous studies that the prolonging of RT in this 379 task is not solely a consequence of bradykinesia, but instead inclusive of motor planning deficits or slowness in information processing ⁹. To separate out contributions to RT prolongation, the lack of 380 381 correlation between our motor planning measure and RT across all cohorts becomes of particular interest. This result suggests that, at least in our task, RT is not merely an output measure reflecting 382 383 the severity of motor planning deficits, but the prolongation observed is likely also influenced by slowness in other cortical processes, potentially visuospatial circuitry ^{46,47}. 384

385 A key difference to highlight between previous work on simple and choice RT tasks and our study is 386 the freedom of the participant to choose their own grasp, as opposed to the enforcement of an 387 instructed action. Therefore one cannot directly compare RT measurements between such tasks and 388 our study. Of course, the process of motor planning may continue beyond home-pad release and thus 389 our measure of RT alone may not capture the full duration of motor planning. Consequently, the 390 prolongation of MT seen with patient groups in this task likely does not solely reflect the time to execute the reach-to-grasp movement but may incorporate a fraction of planning time as well, perhaps 391 explaining the insignificant but slight delay for MCI patients ⁴⁸. Kinematic comparisons between patient 392 393 groups of hand and digit posture over the course of the reach flight trajectory would yield a more 394 accurate measurement of planning time and aid elucidation in future work.

Notably, our halfwidth measure did correlate with disease severity for MCI patients, with a lower global cognitive score relating to worsened task performance – indicative of a more globally unified pathology. Provided that, as mentioned previously, motor planning deficits are seemingly only observed in MCI patients for tasks of higher cognitive load ¹⁶, it could be implied that those patients who have more severe global impairment might be more sensitive to task difficulty, and despite the physical action of the task being simple, the added ambiguous context and choice freedom might provide sufficient cognitive load to induce minor deficits.

402 The pathological neural circuitry underlying the observed deficits in our task could be driven by several 403 mechanisms. The underlying deficits driving motor planning impairment in MCI patients could be 404 wide-ranging across the cortex given the non-specific inclusion criteria used in this study, limiting any 405 mechanistic conclusions for this cohort. For PD, the wide range of erroneous cortical processes are primarily associated with dysfunctional cortico-striatal-thalamic networks ⁴⁹, resulting from 406 407 progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). By the point of 408 motor symptom onset and thus diagnosis, around half the dopaminergic neurons in the SNc are 409 degenerated ⁵⁰, having already resulted in various prodromal non-motor symptoms. This initial 410 degeneration is associated with significant loss of cortico-cortical projecting pyramidal neurons in the 411 pre-supplementary motor area (pre-SMA)⁵¹, an area vital for the selection of and preparation for 412 movements required, potentially explaining the impairments observed in our study. Furthermore, 413 early disease evolution in the prodromal phase is also associated with alterations to motor cortical 414 excitability and plasticity. Specifically, loss of long-term potentiation and depression, reduced intracortical inhibition, and enhanced plasticity induced by paired associative stimulation ^{52,53}. In 415 416 keeping with previous discussion points, the extent of alterations have inconsistent correlations with UPDRS scoring ⁵². These changes could be explained by dopamine deficiency decreasing thalamo-417 cortical output ⁵²; such mechanisms might also influence pre-SMA functioning. However, it is important 418

to consider that cellular vulnerability, induced by dopamine depletion/dysregulation, glutamate
 excitotoxicity, protein aggregation, or neuroinflammation, are also credible mechanisms of pre-SMA
 dysfunction ^{51,54}.

On another note, one of the essential parts of motor planning is reliance upon successful sensory 422 feedback. For a task whereby grasp action is driven by comfort preferences ^{55,56}, one might expect that 423 424 after performing a less comfortable movement, feedback would facilitate adaptive planning over the course of the experiment ^{57,58}, illustrated by a reduction in uncertainty over time. One contributor to 425 the deficits observed in our task might therefore be attributed to impaired proprioceptive sensory 426 427 feedback; precedent for the presence of sensory deficits in PD comes predominantly from freezing of gait and reaching studies ⁵⁹⁻⁶². Furthermore, altered perception of their own movements ^{59,63} or of the 428 target object itself ^{64,65}, would lead to suboptimal motor planning for the task at hand ⁶⁶. It remains to 429 be explored whether those patients who show greater sensory deficits would consequently perform 430 431 worse at motor planning in ambiguous contexts.

Our approach in assessing motor planning deficits in a reach-to-grasp task demonstrated that patients with Parkinson's disease show greater uncertainty in ambiguous contexts compared to healthy controls. Furthermore, our finding that disease severity was not an influencing factor, revealed the independency of pathological motor planning circuitry from basic motor dysfunction. The robust performance of our measure as a pathology classifier for those in the earlier stages of disease progression showcases the utility of it as a potential diagnostic marker, aiding the formation of a wider clinical picture of the manifestations of Parkinson's disease.

439

References

- Ding, W., Ding, L. J., Li, F. F., Han, Y. & Mu, L. Neurodegeneration and cognition in Parkinson's
 disease: a review. *Eur Rev Med Pharmacol Sci* 19, 2275-2281 (2015).
 Sharpe, M. H., Cormak, S. A. & Say, D. S. Motor planning in Parkinson patients.
- 442 2 Sharpe, M. H., Cermak, S. A. & Sax, D. S. Motor planning in Parkinson patients.
- 443 *Neuropsychologia* **21**, 455-462, doi:<u>https://doi.org/10.1016/0028-3932(83)90002-7</u> (1983).
- Goldenberg, G., Wimmer, A., Auff, E. & Schnaberth, G. Impairment of motor planning in
 patients with Parkinson's disease: evidence from ideomotor apraxia testing. *J Neurol Neurosurg Psychiatry* 49, 1266-1272, doi:10.1136/jnnp.49.11.1266 (1986).
- 447 4 Bowen, F. P., Hoehn, M. M. & Yahr, M. D. Parkinsonism: Alterations in spatial orientation as
 448 determined by a route-walking test. *Neuropsychologia* 10, 355-361,
 449 doi:https://doi.org/10.1016/0028-3932(72)90027-9 (1972).
- 450 5 Evarts, E. V., Teräväinen, H. & Calne, D. B. Reaction time in Parkinson's disease. *Brain* 104, 167-186, doi:10.1093/brain/104.1.167 (1981).
- Kutukcu, Y., Marks, W. J., Goodin, D. S. & Aminoff, M. J. Simple and choice reaction time in
 Parkinson's disease. *Brain Research* 815, 367-372, doi:<u>https://doi.org/10.1016/S0006-</u>
 8993(98)01060-9 (1999).
- 455 7 Sanes, J. N. Information processing deficits in Parkinson's disease during movement.
 456 *Neuropsychologia* 23, 381-392, doi:<u>https://doi.org/10.1016/0028-3932(85)90024-7</u> (1985).

457	8	Fasano, A., Mazzoni, A. & Falotico, E. Reaching and Grasping Movements in Parkinson's
458		Disease: A Review. Journal of Parkinson's Disease 12, 1083-1113, doi:10.3233/JPD-213082
459		(2022).
460	9	Johnson, A. M. <i>et al.</i> Visual inspection time in Parkinson's disease: deficits in early stages of
461		cognitive processing. <i>Neuropsychologia</i> 42 , 577-583,
462		doi:10.1016/j.neuropsychologia.2003.10.011 (2004).
463	10	Brown, R. G., Jahanshahi, M. & Marsden, C. D. Response choice in Parkinson's disease. The
464		effects of uncertainty and stimulus-response compatibility. Brain 116 (Pt 4), 869-885,
465		doi:10.1093/brain/116.4.869 (1993).
466	11	Jahanshahi, M., Brown, R. G. & Marsden, C. D. Simple and choice reaction time and the use
467		of advance information for motor preparation in Parkinson's disease. Brain 115 (Pt 2) , 539-
468		564. doi:10.1093/brain/115.2.539 (1992).
469	12	Sheridan, M. R., Flowers, K. A. & Hurrell, J. Programming and execution of movement in
470		Parkinson's disease <i>Brain</i> 110 (Pt 5) 1247-1271, doi:10.1093/brain/110.5.1247 (1987)
471	13	Stelmach, G. E., Castiello, U. & Jeannerod, M. Orienting the finger opposition space during
472	10	nrehension movements / Mat Behav 26 , 178-186, doi:10.1080/00222895.1994.9941672
473		(1994)
473	14	Petersen B C Mild cognitive impairment as a diagnostic entity <i>Lintern Med</i> 256 183-194
475	T	doi:10 1111/i 1365-2796 2004 01388 x (2004)
476	15	Tinnett W I & Sergio I E Visuomotor integration is impaired in early stage Alzheimer's
470	15	disease Brain Res 1102 92-102 doi:10.1016/i brainres 2006.04.049 (2006)
477	16	Salek V Anderson N D & Sergio L Mild cognitive impairment is associated with impaired
470	10	visual-motor planning when visual stimuli and actions are incongruent. <i>Eur Neural</i> 66, 282-
475		202 doi:10.11E0/000221040 (2011)
400 101	17	295, 001.10.1159/000551049 (2011). Kluger A. et al. Patterns of Motor Impairment in Normal Aging Mild Cognitive Decline, and
401	1/	Early Alzhoimor' Disease. The Journals of Carontology: Series R 528 , D28, D20
40Z 102		dai:10.1002/garanh/52P.1.D29 (1007)
405 101	10	Schade S. Mollenhauer P. & Trankwalder C. Levedona Equivalent Dece Conversion Easters:
404 405	10	Schlade, S., Mohenhader, B. & Henkwalder, C. Levodopa Equivalent Dose Conversion Factors.
405		An opualed Proposal including opicapone and samanide. <i>Novement Disorders</i> clinical
400	10	Produce 7, 545-545, doi. $\underline{\text{IIII}}$ (2020).
487	19	Ambiguous Sattings is Sansitive to Driver Object Mation, bioRviv, 2022 2011 2020 567846
400		Anibiguous Sellings is Sensitive to Phor Object Motion. <i>Diorxiv</i> , 2023.2011.2020.567846,
489	20	$\begin{array}{c} \text{doi:10.1101/2023.11.20.567846} (2024). \end{array}$
490	20	wood, D. K. & Goodale, IVI. A. Selection of wrist posture in conditions of motor ambiguity.
491	24	Exp Brain Res 208 , 607-620, doi:10.1007/s00221-010-2509-7 (2011).
492	21	Chen, J. et al. Predictors of cognitive impairment in newly diagnosed Parkinson's disease with
493		normal cognition at baseline: A 5-year cohort study. Front Aging Neurosci 15 , 1142558,
494		doi:10.3389/fnagi.2023.1142558 (2023).
495	22	Kawasaki, T. <i>et al.</i> Motor planning error in Parkinson's disease and its clinical correlates. <i>PLoS</i>
496		<i>One</i> 13 , e0202228, doi:10.1371/journal.pone.0202228 (2018).
497	23	Schneider, J. S., Sendek, S. & Yang, C. Relationship between Motor Symptoms, Cognition, and
498		Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease. PLOS ONE 10,
499		e0123231, doi:10.1371/journal.pone.0123231 (2015).
500	24	Choudhury, S. et al. Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is
501		Improved by Standard Treatment. <i>Sci Rep</i> 9 , 19504, doi:10.1038/s41598-019-55321-5 (2019).
502	25	Gauggel, S., Rieger, M. & Feghoff, T. Inhibition of ongoing responses in patients with
503		Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 75, 539-544 (2004).
504	26	Moriyasu, S., Shimizu, T., Honda, M., Ugawa, Y. & Hanajima, R. Motor cortical plasticity and
505		its correlation with motor symptoms in Parkinson's disease. eNeurologicalSci 29, 100422,
506		doi:https://doi.org/10.1016/j.ensci.2022.100422 (2022).

507	27	Domellöf, M. E., Elgh, E. & Forsgren, L. The relation between cognition and motor
508		dysfunction in drug-naive newly diagnosed patients with Parkinson's disease. <i>Movement</i>
509		<i>Disorders</i> 26 . 2183-2189. doi:https://doi.org/10.1002/mds.23814 (2011).
510	28	Huber, S. J., Christy, J. A. & Paulson, G. W. Cognitive heterogeneity associated with clinical
511		subtypes of Parkinson's disease. <i>Cognitive and Behavioral Neurology</i> 4 , 147-157 (1991).
512	29	Armstrong, M. I. & Okun, M. S. Diagnosis and Treatment of Parkinson Disease: A Review
513	20	<i>Jama</i> 323 548-560 doi:10.1001/jama.2019.22360 (2020)
514	30	Berg D et al MDS research criteria for prodromal Parkinson's disease Movement Disorders
515	50	30 1600-1611 doi:https://doi.org/10.1002/mds.26431 (2015)
516	31	Wallace F R Segerstrom S C van Horne C G Schmitt F A & Koehl L M Meta-Analysis
517	51	of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression
518		Neuronsychology Review 37 149-160 doi:10.1007/s11065-021-09502-7 (2022)
510	30	Kehagia A A Barker B A & Robbins T W Neuronsychological and clinical beterogeneity of
520	52	cognitive impairment and dementia in nations, with Parkinson's disease. The Lancet
520		Neurology 9 1200-1213 (2010)
521	22	Poheger M. Kalhe F. & Lienelt-Scarfone I. Progression of Cognitive Decline in Parkinson's
522	22	Disease Journal of Darkinson's Disease 9, 192, 102, doi:10.2222/JDD.191206.(2019)
525	24	Aarcland, D. at al. Mild cognitive impairment in Parkinson disease: a multicenter peoled
524	54	Aarsiand, D. et di. Wild Cognitive impairment in Parkinson disease. a multicenter pooled
525	25	Allalysis. Neurology 75, 1002-1009 (2010). Nasroddina, 7, 5, at al. The Montreal Cognitive Assessment, MaCA: a brief screening tool for
520	22	mild cognitive impairment lournal of the American Coriatrics Society 52 , 605, 600 (2005)
527	26	Initia Cognitive Impairment. Journal of the American Genatics Society 55 , 695-699 (2005).
528	30	(1004)
529	27	(1994). Relactrice D. & Cohanira A. U. V. Darkinson disease European Journal of Neurolanu 37 , 27
530	37	Balestrino, R. & Schapira, A. H. V. Parkinson disease. European Journal of Neurology 21 , 27-
531	20	42, doi: <u>nttps://doi.org/10.1111/ene.14108</u> (2020).
532	38	Barbeau, A. L-dopa therapy in Parkinson's disease: a childar review of hine years experience.
533	20	Can Med Assoc J 101 , 59-68 (1969).
534	39	Beaulieu-Boire, I. & Lang, A. E. Benavioral effects of levodopa. <i>Novement Disorders</i> 30 , 90-
535	40	$102, 001:\frac{mmps:}{001}$ (2015).
536	40	Gui, A. & Yousaf, J. Effect of levodopa on frontal-subcortical and posterior cortical functioning
537		In patients with Parkinson's disease. Singapore Med J 60 , 414-417,
538		dol:10.11622/smedj.2018116 (2019).
539	41	Funklewiez, A. <i>et al.</i> Effects of levodopa and subtralamic nucleus stimulation on cognitive
540		and affective functioning in Parkinson's disease. <i>Niov Disord</i> 21 , 1656-1662,
541	42	dol:10.1002/mds.21029 (2006).
542	42	Catalan, M. J. <i>et al.</i> Levodopa infusion improves impulsivity and dopamine dysregulation
543		syndrome in Parkinson's disease. <i>Movement Disorders</i> 28 , 2007-2010,
544	40	doi: <u>nttps://doi.org/10.1002/mds.25636</u> (2013).
545	43	Kiani, M. M., Heidari Beni, M. H. & Aghajan, H. Aberrations in temporal dynamics of cognitive
546		processing induced by Parkinson's disease and Levodopa. Sci Rep 13, 20195,
547		doi:10.1038/s41598-023-4/410-3 (2023).
548	44	Cortes, R., Gueye, B., Pazos, A., Probst, A. & Palacios, J. Dopamine receptors in human brain:
549		autoradiographic distribution of D1 sites. <i>Neuroscience</i> 28 , 263-273 (1989).
550	45	Camps, M., Cortes, R., Gueye, B., Probst, A. & Palacios, J. Dopamine receptors in human
551		brain: autoradiographic distribution of D2 sites. <i>Neuroscience</i> 28 , 275-290 (1989).
552	46	Nguyen, V. Q., Gillen, D. L. & Dick, M. B. Memory for unfamiliar faces differentiates mild
553		cognitive impairment from normal aging. Journal of Clinical and Experimental
554		Neuropsychology 36 , 607-620, doi:10.1080/13803395.2014.919992 (2014).
555	47	Chehrehnegar, N. et al. Early detection of cognitive disturbances in mild cognitive
556		impairment: a systematic review of observational studies. <i>Psychogeriatrics</i> 20 , 212-228,
557		doi:https://doi.org/10.1111/psyg.12484 (2020).

558 559	48	Dijkerman, H. C., McIntosh, R. D., Schindler, I., Nijboer, T. C. & Milner, A. D. Choosing between alternative wrist postures: action planning needs perception. <i>Neuropsychologia</i> 47 , 1476-
560	40	1482, doi:10.1016/J.neuropsychologia.2008.12.002 (2009).
501	49	Foriani, G. & Obeso, J. A. A Cortical Pathogenic Theory of Parkinson's Disease. <i>Neuron</i> 99 ,
502	50	$1110-1128, 001: \underline{\text{mups}}/(001.01g/10.1016/J.neuron.2018.07.028} (2018).$
503	50	Fedriney, J. M. & Lees, A. J. AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA
564	F 4	REGIONAL SELECTIVITY. Brain 114, 2283-2301, doi:10.1093/brain/114.5.2283 (1991).
505	51	MacDonald, V. & Halliday, G. M. Selective loss of pyramidal neurons in the pre-
500		supplementary motor cortex in Parkinson's disease. <i>Movement Disorders</i> 17, 1100-1173,
507	52	dol:10.1002/mds.10258 (2002).
508	52	Kishore, A., Joseph, T., Velayuunan, B., Popa, T. & Meunier, S. Early, severe and bilateral loss
509		of LIP and LID-like plasticity in motor cortex (MI) in de novo Parkinson's disease. <i>Clinical</i>
570	52	Neurophysiology 123, 822-828, doi: <u>https://doi.org/10.1016/j.clinph.2011.06.034</u> (2012).
5/1	53	KOJOVIC, MI. <i>et al.</i> Functional reorganization of sensorimotor cortex in early Parkinson disease.
572	F 4	Neurology 78 , 1441-1448, dol:10.1212/ WNL.0001363182530500 (2012).
5/3	54	Dexter, D. I. & Jenner, P. Parkinson disease: from pathology to molecular disease
574		mechanisms. Free Radical Biology and Medicine 62 , 132-144,
5/5		dol: <u>https://dol.org/10.1016/j.freeradblomed.2013.01.018</u> (2013).
5/6	55	Mark, L. S. <i>et al.</i> Postural dynamics and the preferred critical boundary for visually guided
5//		reaching. J Exp Psychol Hum Percept Perform 23, 1365-1379, doi:10.1037//0096-
5/8	50	1523.23.5.1365 (1997).
579	56	Stasik, S. & Mark, L. S. in Studies in perception and action VIII 23-26 (Psychology Press,
580		
581	57	Henriques, D. Y. P. & Cressman, E. K. Visuomotor Adaptation and Proprioceptive
582		Recalibration. <i>Journal of Motor Benaviol</i> 44 , 435-444, doi:10.1080/00222895.2012.659232
583	F 0	(2012). Shadmahr D. Smith M. A. S. Krakawar L. W. Error Correction. Sourcem, Dradiction, and
584	58	Adaptation in Mater Central Annual Baview of Neuroscience 22 , 90, 109
585		Adaptation in Motor Control. Annual Review of Neuroscience 33, 89-108,
580	50	dol:https://dol.org/10.1146/annurev-neuro-060909-153135 (2010).
587	59	Silveira, C. R. <i>et al.</i> Disentanging perceptual judgment and online feedback dencits in
588		Parkinson's freezing of gait. J Neurol 262 , 1629-1636, doi:10.1007/s00415-015-7759-7
569	60	(2013). Carst T. Marsdan J. & Freeman J. Lewer Limb Semateconcery Discrimination Is Impaired in
590	60	Gorst, T., Marsden, J. & Freeman, J. Lower Limb Somatosensory Discrimination is impaired in
291		Febple With Parkinson's Disease: Novel Assessment and Associations with Balance, Gall, and
592	61	Falls. NOV Disola Cilli Place 6, 593-600, doi:10.1002/mac3.12831 (2019).
595	01	Timing Processing in Parkinson's Disease, Journal of Motor Pabaviar 51, 561, 571
594		
595	62	U01.10.1080/00222895.2018.1528204 (2019).
590	02	KONCZAK, J. <i>et al.</i> Proprioception and motor control in Parkinson's disease. <i>J Mot Benuv</i> 41 ,
597	62	543-552, UOI.10.3200/35-09-002 (2009).
598	03	koop, M. M., Hill, B. C. & Bronie-Stewart, Π. M. Perceptual errors increase with movement
599		duration and may contribute to hypokinesia in Parkinson's disease. <i>Neuroscience</i> 243 , 1-13, doi:10.1016/j.neuroscience.2012.02.026 (2012)
600	64	Armstrong B. A. Visual signs and sumptoms of Barkinson's disease. <i>Clinical and Experimental</i>
601	04	Armstrong, R. A. Visual signs and symptoms of Parkinson's disease. <i>Clinical and Experimental</i>
602	C.L	Optometry 91, 129-138, doi: <u>https://doi.org/10.1111/j.1444-0938.2007.00211.X</u> (2008).
604	20	Annistrong, R. A. Oculo-visual Dystanction in Parkinson's Disease. J Parkinson's DIS 5, 715-
004 605	66	120, UUI.1U.3233/JPU-130000 (2013). Diodorich N. L. Paman P. Lourgans S. & Conta C. C. Drograssiva warsoning of anoticlast
605	00	chromatic processing deficits in Parkinson disease. Arch Neurol 50 , 1240, 1252
607		doi:10.1001/orchnour E0.8.1240 (2002)
007		uui.tu.tuut/ai uiiileui.J3.0.t243 (2002).